| Added by | pcoopman |
|---|---|
| Group name | EquipePC |
| Item Type | Journal Article |
| Title | [Resistance to BRAF inhibitors: A lesson from clinical observations] |
| Creator | Dahmani et al. |
| Author | Cylia Dahmani |
| Author | Eulalie Corre |
| Author | Sarah Dandou |
| Author | Alain Mangé |
| Author | Ovidiu Radulescu |
| Author | Peter J. Coopman |
| Author | Pierre Cuq |
| Author | Romain M. Larive |
| Abstract | The MAPK/ERK pathway is an essential intracellular signaling pathway. Its deregulation is involved in tumor transformation and progression. The discovery of activating mutations of BRAF in various cancers has opened new therapeutic avenues with BRAF protein kinase inhibitors. Depending on the type of cancers, these inhibitors have shown either insufficient efficacy due to primary resistance of tumor cells or transient efficacy due to the development of acquired resistance. In this review, we revisit the discoveries that led to the development of BRAF inhibitors and detail the molecular and cellular mechanisms of resistance in cancers treated with these inhibitors. Understanding these mechanisms is crucial for developing more efficient therapeutic strategies. |
| Publication | Medecine Sciences: M/S |
| Volume | 38 |
| Issue | 6-7 |
| Pages | 570-578 |
| Date | 2022 Jun-Jul |
| Journal Abbr | Med Sci (Paris) |
| Language | fre |
| DOI | 10.1051/medsci/2022083 |
| ISSN | 1958-5381 |
| Short Title | [Resistance to BRAF inhibitors |
| Library Catalog | PubMed |
| Extra | PMID: 35766855 |
| Tags | Cell Line, Tumor, Drug Resistance, Neoplasm, first-last-corresponding, Humans, MAP Kinase Signaling System, Mutation, Neoplasms, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, review |
| Date Added | 2022/07/29 - 18:09:21 |
| Date Modified | 2023/11/13 - 17:17:51 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
